Home > Healthcare & Medical Devices > Helicobacter Pylori Testing Market
Helicobacter Pylori Testing Market size was valued at over USD 447 million in 2022. Driven by the increasing instances of peptic ulcers, the market is slated to register over 6.5% CAGR from 2023 to 2032.
People infected with helicobacter pylori are prone to gastric ulcers as the bacteria can damage the inner protective lining of their intestine as well as stomach. Based on that co-relation, growing cases of gastric ulcers across the globe are primarily fueling the demand for helicobacter pylori testing.
To get more details on this report: Request Free Sample PDF
Helicobacter pylori infection is typically diagnosed through an invasive procedure, which entails biopsy and endoscopy, and requires advanced operational skills for precisely diagnosing and identifying the appropriate treatment method. However, the lack of trained professionals in nations with limited healthcare resources may affect the disease testing rates, dampening the market progress. Many low and middle-income economies lack the hospital and medical training infrastructure needed to highly skilled physicians. Helicobacter pylori treatment also poses other challenges for physicians as no first-line therapy can treat the infection for all patients.
|Market Size in 2022:||USD 447 million|
|Forecast Period:||2023 to 2032|
|Forecast Period 2023 to 2032 CAGR:||6.5%|
|2032 Value Projection:||USD 876 million|
|Historical Data for:||2018 to 2022|
|No. of Pages:||204|
|Tables, Charts & Figures:||337|
|Segments covered:||Test Type, Method, End-use, and Region.|
|Pitfalls & Challenges:|
To get details on how to order this report click here
On the basis of the test, the helicobacter pylori testing market is bifurcated into invasive and non-invasive helicobacter pylori tests. Amongst them, invasive helicobacter test segment is poised to register a 6.5% CAGR from 2023 to 2032, driven by the efficacy and cost-effectiveness of rapid urease tests. The demand for invasive testing method is also high among patients do not correspond well to antibiotic therapy, have symptoms of severe gastric problems, and further require gastric endoscopy.
To tailor this report to your specific requirements: Customize this Report
On the basis of the method, the helicobacter pylori testing market is categorized into laboratory-based tests and point-of-care (POC) tests. The POC tests segment accounted for a business share of more than 35% in 2022, due to its non-invasive nature and its ability to deliver fast results. This is also attributed to collaborative research initiatives by leading industry giants and increasing R&D spending, which is further encouraging technological advancements as well as new product launches.
To check discounted pricing for this report: Request Discount
Based on end-use, the helicobacter pylori testing market is segmented into clinics, hospitals, diagnostic labs, and others. The clinic segment is projected to depict over 6% CAGR from 2023 to 2032, owing to the rising patient preference for clinics due to affordability and quality care. This is driven by the high-quality treatment and quick assistance offered by clinics, which provides the desired treatment results at a reasonable cost. In addition, the high-end services offered by clinics through effective disease management strategies are further set to spur segment expansion.
Asia Pacific helicobacter pylori testing market was valued at more than USD 100 million in 2022 and is further expected to witness over 8.5% CAGR from 2023 to 2032. Revenue growth is slated to be fueled by the rising occurrences of infectious ailments and increasing aging population in the region. Poor healthcare infrastructure and low awareness about good sanitary practices across developing APAC economies is further projected to fuel the demand for helicobacter pylori tests.
Some industry leaders in the h. pyroli testing sector include Avanos Corporate, Bio-Rad Laboratories, Biohit Oyj, bioMerieux SA, Cardinal Health, Inc., Gulf Coast Scientific, Medline Industries, among others. Firms are increasingly leveraging on mergers and acquisitions to elevate their market penetration.
In the initial months of 2020, COVID-19 made a severe negative impact on the h. pylori testing industry. Many h. pylori patients avoided hospital visits on account of the rapidly increasing COVID-19 cases and mortality rates, which overwhelmed healthcare facilities and spread infection fears among the global population. Additionally, the infection risks associated with invasive helicobacter pylori testing at point-of-care treatment units also led to disruption in the sector.
Since the route of virus transmission is nasal or oral, the non-invasive tests such as the urea breath tests (UBT) were also impacted as they held a high possibility of COVID-19 transmission. Now, as successful vaccination drives turn COVID-19 into an afterthought, the market is expected to bounce back in a notable manner.
Global helicobacter pylori testing market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments: Click here to buy sections of this report
Click here to buy sections of this report
The above information is provided for the following regions and countries: